Is Mounjaro a diabetes medication, or a weight-loss treatment?

How the MHRA's two licences came about, and why they matter

The UK regulator (MHRA) granted tirzepatide its first UK authorisation for type 2 diabetes, then a separate authorisation for weight management as SURMOUNT programme data matured. NICE reviewed the weight-management evidence and published its appraisal (TA1026) in December 2024, recommending tirzepatide for adults with a BMI of 35 or above alongside at least one weight-related comorbidity within an NHS specialist pathway, with ethnic-background thresholds 2.5 kg/m² lower for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. NICE TA1026 is worth reading if you want the full NHS eligibility picture.

The diabetes and weight licences coexist because tirzepatide genuinely does both things, by design. Activating the GIP receptor alongside GLP-1 receptors improves insulin secretion and insulin sensitivity, which matters for blood-sugar control in type 2 diabetes. The same dual action slows gastric emptying and reduces appetite, which drives the weight-loss outcomes. The mechanism is the same; the licensed population and the clinical monitoring differ. That distinction is why a prescriber's assessment (not a symptom checker) is the right starting point.

A question our prescribers hear most weeks is whether someone with both type 2 diabetes and obesity is being prescribed Mounjaro for their weight, their blood sugar, or both. In practice, a specialist or GP decides which indication is primary and structures the clinical review accordingly. If you are uncertain which applies to your situation, the answer lives in a consultation, not a webpage.

What SURMOUNT-1 and the diabetes trials actually showed

In the SURMOUNT-1 trial, published in the New England Journal of Medicine, adults with obesity but without diabetes lost an average of around 20–21% of body weight over 72 weeks at the 15mg dose. Those figures are from a tightly controlled trial with lifestyle support; real-world outcomes vary and no result is guaranteed. The SURMOUNT-5 head-to-head trial (published in the NEJM, 2025) compared tirzepatide directly with semaglutide 2.4mg in adults with obesity and found tirzepatide produced greater average weight reduction over 72 weeks, a fact relevant when patients ask how Mounjaro sits alongside other weight-loss medicines.

The SURPASS diabetes trial programme covered tens of thousands of participants across the broader tirzepatide clinical programme (SURPASS plus SURMOUNT combined) and showed meaningful HbA1c reductions alongside weight loss in type 2 diabetes. For anyone exploring whether Mounjaro is effective for diabetes, the SURPASS data give a more complete picture than the weight-only trials, and our dedicated page on Mounjaro for type 2 diabetes goes further into what the evidence means in practice. The practical takeaway from both sets of evidence: this is a medicine with a well-documented mechanism and substantial trial data; it is not an off-label experiment in either indication.

Safety profile: what applies to both licences, and what differs

The side-effect profile is largely the same whether Mounjaro is prescribed for diabetes or weight management. Gastrointestinal effects (nausea, loose stools, constipation, indigestion, reduced appetite) are the most commonly reported, typically more noticeable after starting or a dose increase, and often settling within a couple of weeks. Injection-site reactions, headache and fatigue are also reported. The NHS tirzepatide medicines page lists the full side-effect categories in plain language.

One safety point that shifts between the two licensed groups: people using Mounjaro for diabetes, particularly those also taking a sulphonylurea or insulin, face a higher risk of hypoglycaemia. That monitoring requirement sits with the prescribing clinician. For both groups, pancreatitis is a known but infrequent risk, the MHRA highlighted this in a January 2026 Drug Safety Update. Severe, persistent stomach pain that radiates to the back, with or without vomiting, is a reason to seek urgent medical help. If you are on tirzepatide and using an oral contraceptive, NHS guidance recommends adding a barrier method for the first four weeks of treatment and for four weeks after each dose increase, as pill absorption may be reduced. Discuss any interactions, including thyroid medication, with your prescriber before starting.

Mounjaro is not recommended during pregnancy, breastfeeding, or when trying to conceive. It is not licensed for under-18s. These are firm clinical boundaries in both the diabetes and weight-management contexts.

Private access through a regulated pharmacy: what that involves

For weight management, people who do not meet the NHS's phased eligibility criteria, or who prefer not to wait, can access Mounjaro privately through a GPhC-registered pharmacy after a clinical consultation. The full Mounjaro overview explains what private treatment involves. For context on how UK private pricing has shifted since Eli Lilly's September 2025 list-price change, the price increase page covers that story. At nume, a GPhC-registered Independent Prescriber reviews every consultation, a real clinician reads your health information the same day, not software. Treatment dispatched before the 12pm cut-off leaves for next-working-day DPD delivery in plain packaging.

For diabetes management specifically, Mounjaro is typically prescribed by a GP or specialist; a private weight-loss pharmacy is not the usual route. If your reason for asking is mainly about weight loss and you want to understand your options, speaking to our prescribers is the right first step.